EUCTR2013-004973-29-GR进行中（未招募）不适用
A safety open-label study of Gevokizumab in the treatment of patients with chronic non-infectious Uveitis disease, an eXtension study. The EYEGUARD-X study. - EYEGUARD-X
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- either completed participation to one of the following : CL3-78989-002 open label extension, or X052130/CL3-78989-005 double masked period or open label period, or X052131/CL3-78989-006 double masked period or open label period, or currently benefiting from gevokizumab compassionate use after participation in gevokizumab uveitis studies,
- •- Able to receive the first injection of gevokizumab within 6 weeks after the last study drug administration
- •- Male or female, age =18 (or legal age of majority in the country) at selection
- •- For subjects with reproductive potential, a willingness to use highly effective contraceptive measures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 270
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •- Meeting criteria for discontinuation of any of gevokizumab uveitis previous study.
- •- Infectious uveitis and masquerade syndrome.
- •- History of severe allergic or anaphylactic reaction to study drug administration during previous study or to gevokizumab or any of its excipient.
- •- Currently active Infectious disease.
研究者
相似试验
进行中（未招募）
1 期
A Study of Reslizumab Subcutaneous Dosing in Patients 12 Years of Age and Older with Severe Eosinophilic AsthmaEUCTR2016-004661-23-BETeva Branded Pharmaceutical Products R&D, Inc.360
进行中（未招募）
1 期
A Study of Reslizumab Subcutaneous Dosing in Patients 12 Years of Age and Older with Severe Eosinophilic AsthmaEUCTR2016-004661-23-ROTeva Branded Pharmaceutical Products R&D, Inc.391
尚未招募
Unknown
Safety evaluation of the capsules containing Valeriana fauriei root (VF) extract.JPRN-UMIN000049908agoya City University Hospital10
已完成
不适用
Open Label Study of GLYX-13 in Subjects with Neuropathic Paieuropathic pain including post-herpetic neuralgia, diabetic neuropathySigns and SymptomsISRCTN17197655aurex, Inc. (USA)100
进行中（未招募）
不适用
Safety and tolerability of dabigatran etexilate in adolescentsVenous Thrombotic EventMedDRA version: 14.1Level: LLTClassification code 10066899Term: Venous thromboembolismSystem Organ Class: 10047065 - Vascular disordersEUCTR2008-006866-27-Outside-EU/EEABoehringer Ingelheim (Canada) Ltd./Ltée8